- Home
- CRBU vs PBYI Comparison
CRBU vs PBYI Comparison
Compare CRBU & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBU
- PBYI
- Stock Information
- Founded
- CRBU 2011
- PBYI 2010
- Country
- CRBU United States
- PBYI United States
- Employees
- CRBU N/A
- PBYI N/A
- Industry
- CRBU Medicinal Chemicals and Botanical Products
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- CRBU Health Care
- PBYI Health Care
- Exchange
- CRBU Nasdaq
- PBYI Nasdaq
- Market Cap
- CRBU 151.2M
- PBYI 153.2M
- IPO Year
- CRBU 2021
- PBYI N/A
- Fundamental
- Price
- CRBU $1.52
- PBYI $2.98
- Analyst Decision
- CRBU Strong Buy
- PBYI Strong Buy
- Analyst Count
- CRBU 5
- PBYI 1
- Target Price
- CRBU $11.80
- PBYI $7.00
- AVG Volume (30 Days)
- CRBU 1.6M
- PBYI 808.8K
- Earning Date
- CRBU 03-10-2025
- PBYI 02-27-2025
- Dividend Yield
- CRBU N/A
- PBYI N/A
- EPS Growth
- CRBU N/A
- PBYI 492.79
- EPS
- CRBU N/A
- PBYI 0.47
- Revenue
- CRBU $11,475,000.00
- PBYI $243,569,000.00
- Revenue This Year
- CRBU N/A
- PBYI N/A
- Revenue Next Year
- CRBU N/A
- PBYI N/A
- P/E Ratio
- CRBU N/A
- PBYI $6.41
- Revenue Growth
- CRBU N/A
- PBYI 6.30
- 52 Week Low
- CRBU $1.50
- PBYI $2.23
- 52 Week High
- CRBU $8.33
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- CRBU 34.82
- PBYI 46.28
- Support Level
- CRBU $1.50
- PBYI $2.92
- Resistance Level
- CRBU $1.69
- PBYI $4.06
- Average True Range (ATR)
- CRBU 0.13
- PBYI 0.25
- MACD
- CRBU -0.01
- PBYI -0.04
- Stochastic Oscillator
- CRBU 3.70
- PBYI 5.26
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.